{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:32:31Z","timestamp":1787758351223,"version":"build-2784847793"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Hereditary retinal dystrophies (HRDs), such as retinitis pigmentosa, Leber's congenital amaurosis (LCA), Usher syndrome, and retinoschisis, are a group of genetic retinal disorders exhibiting both genetic and phenotypic heterogeneity. Symptoms include progressive retinal degeneration and constricted visual field. Some patients will be legal or completely blind. Advanced sequencing technologies improve the genetic diagnosis of HRD and lead to a new era of research into gene-targeted therapies. Following the first Food and Drug Administration approval of gene augmentation therapy for LCA caused by\n                      <jats:italic toggle=\"yes\">RPE65<\/jats:italic>\n                      mutations, multiple clinical trials are currently underway applying different techniques. In this review, we provide an overview of gene therapy for HRD and emphasize four distinct approaches to gene-targeted therapy that have the potential to slow or even reverse retinal degeneration: (1) viral vector-based and nonviral gene delivery, (2) RNA-based antisense oligonucleotide, (3) genome editing by the Clustered Regularly Interspaced Short Palindromic Repeat\/cas9 system, and (4) optogenetics gene therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tcmj.tcmj_78_22","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T06:56:41Z","timestamp":1665385001000},"page":"367-372","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Gene therapy in hereditary retinal dystrophy"],"prefix":"10.4103","volume":"34","author":[{"given":"Jia-Ying","family":"Chien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240828","doi-asserted-by":"crossref","first-page":"33248","DOI":"10.1038\/srep33248","article-title":"Panel-based population next-generation sequencing for inherited retinal degenerations","volume":"6","author":"Carrigan","year":"2016","journal-title":"Sci Rep"},{"key":"R2-4-20240828","doi-asserted-by":"crossref","first-page":"18287","DOI":"10.1038\/srep18287","article-title":"NGS-based Molecular diagnosis of 105 eyeGENE(\u00ae) probands with Retinitis Pigmentosa","volume":"5","author":"Ge","year":"2015","journal-title":"Sci Rep"},{"key":"R3-4-20240828","doi-asserted-by":"crossref","first-page":"23910","DOI":"10.1038\/srep23910","article-title":"Improving the management of Inherited Retinal Dystrophies by targeted sequencing of a population-specific gene panel","volume":"6","author":"Bravo-Gil","year":"2016","journal-title":"Sci Rep"},{"key":"R4-4-20240828","doi-asserted-by":"crossref","first-page":"e0207958","DOI":"10.1371\/journal.pone.0207958","article-title":"Next-generation sequencing identifies unexpected genotype-phenotype correlations in patients with retinitis pigmentosa","volume":"13","author":"Birtel","year":"2018","journal-title":"PLoS One"},{"key":"R5-4-20240828","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/13816810.2019.1675178","article-title":"Next-generation sequencing and its application in diagnosis of retinitis pigmentosa","volume":"40","author":"Salmaninejad","year":"2019","journal-title":"Ophthalmic Genet"},{"key":"R6-4-20240828","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","article-title":"The molecular basis of human retinal and vitreoretinal diseases","volume":"29","author":"Berger","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"R7-4-20240828","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.crvi.2014.01.002","article-title":"Gene therapy for inherited retinal degenerations","volume":"337","author":"Dalkara","year":"2014","journal-title":"C R Biol"},{"key":"R8-4-20240828","doi-asserted-by":"crossref","first-page":"a017111","DOI":"10.1101\/cshperspect.a017111","article-title":"Clinical characteristics and current therapies for inherited retinal degenerations","volume":"5","author":"Sahel","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R9-4-20240828","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/hum.2015.030","article-title":"Gene therapy of inherited retinal degenerations: Prospects and challenges","volume":"26","author":"Trapani","year":"2015","journal-title":"Hum Gene Ther"},{"key":"R10-4-20240828","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.preteyeres.2014.08.001","article-title":"Vector platforms for gene therapy of inherited retinopathies","volume":"43","author":"Trapani","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"R11-4-20240828","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev-neuro-062012-170304","article-title":"Gene therapy for blindness","volume":"36","author":"Sahel","year":"2013","journal-title":"Annu Rev Neurosci"},{"key":"R12-4-20240828","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/311067a0","article-title":"Live recombinant vaccinia virus protects chimpanzees against hepatitis B","volume":"311","author":"Moss","year":"1984","journal-title":"Nature"},{"key":"R13-4-20240828","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nm1365","article-title":"Effective gene therapy with nonintegrating lentiviral vectors","volume":"12","author":"Y\u00e1\u00f1ez-Mu\u00f1oz","year":"2006","journal-title":"Nat Med"},{"key":"R14-4-20240828","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"R15-4-20240828","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/2277-9175.98152","article-title":"Viral and nonviral delivery systems for gene delivery","volume":"1","author":"Nayerossadat","year":"2012","journal-title":"Adv Biomed Res"},{"key":"R16-4-20240828","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: A follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"key":"R17-4-20240828","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-3-319-17121-0_35","article-title":"A comprehensive review of mutations in the MERTK proto-oncogene","volume":"854","author":"Parinot","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"R18-4-20240828","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/a-0811-5480","article-title":"Novel PDE6B mutation presenting with retinitis pigmentosa \u2013 A case series of three patients","volume":"236","author":"Palmowski-Wolfe","year":"2019","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R19-4-20240828","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ymthe.2021.04.024","article-title":"Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations","volume":"29","author":"Dulla","year":"2021","journal-title":"Mol Ther"},{"key":"R20-4-20240828","doi-asserted-by":"crossref","first-page":"xxv","DOI":"10.1016\/j.ajo.2018.08.038","article-title":"The blunt end: Surgical challenges of gene therapy for inherited retinal diseases","volume":"196","author":"Davis","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R21-4-20240828","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","article-title":"Two-year results After AAV2-mediated gene therapy for choroideremia: The Alberta experience","volume":"193","author":"Dimopoulos","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R22-4-20240828","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"R23-4-20240828","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat Med"},{"key":"R24-4-20240828","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1167\/iovs.15-16400","article-title":"Allele-specific inhibition of rhodopsin with an antisense oligonucleotide slows photoreceptor cell degeneration","volume":"56","author":"Murray","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-4-20240828","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.ymthe.2020.08.012","article-title":"Therapy in rhodopsin-mediated autosomal dominant retinitis pigmentosa","volume":"28","author":"Meng","year":"2020","journal-title":"Mol Ther"},{"key":"R26-4-20240828","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R27-4-20240828","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"R28-4-20240828","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.gt.3301110","article-title":"Nonviral gene therapy: Promises and challenges","volume":"7","author":"Li","year":"2000","journal-title":"Gene Ther"},{"key":"R29-4-20240828","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1016\/j.biomaterials.2013.06.002","article-title":"A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium","volume":"34","author":"Koirala","year":"2013","journal-title":"Biomaterials"},{"key":"R30-4-20240828","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtn.2018.11.007","article-title":"Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics","volume":"14","author":"Le","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"R31-4-20240828","first-page":"347","article-title":"Antisense oligonucleotides: Basic concepts and mechanisms","volume":"1","author":"Dias","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"R32-4-20240828","first-page":"14","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr","year":"1998","journal-title":"J Int Assoc Physicians AIDS Care"},{"key":"R33-4-20240828","doi-asserted-by":"crossref","first-page":"E137","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: From antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells"},{"key":"R34-4-20240828","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/2211536602666140110234046","article-title":"Regulation of miRNA processing and miRNA mediated gene repression in cancer","volume":"3","author":"Bajan","year":"2014","journal-title":"Microrna"},{"key":"R35-4-20240828","doi-asserted-by":"crossref","first-page":"109447","DOI":"10.1016\/j.biopha.2019.109447","article-title":"Regulation of cardiac stem cells by microRNAs: State-of-the-art","volume":"120","author":"Gorabi","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"R36-4-20240828","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R37-4-20240828","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: From concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med"},{"key":"R38-4-20240828","doi-asserted-by":"crossref","first-page":"419","DOI":"10.21037\/atm.2020.03.57","article-title":"The potential for microRNA-based therapeutics in retinal disorders","volume":"8","author":"Chu-Tan","year":"2020","journal-title":"Ann Transl Med"},{"key":"R39-4-20240828","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2147\/OTT.S152462","article-title":"Functional miRNAs in breast cancer drug resistance","volume":"11","author":"Hu","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R40-4-20240828","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.exer.2017.06.007","article-title":"Application of CRISPR-Cas9 in eye disease","volume":"161","author":"Wu","year":"2017","journal-title":"Exp Eye Res"},{"key":"R41-4-20240828","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","article-title":"Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product","volume":"169","author":"Ishino","year":"1987","journal-title":"J Bacteriol"},{"key":"R42-4-20240828","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jmb.2016.11.024","article-title":"Deciphering, communicating, and engineering the CRISPR PAM","volume":"429","author":"Leenay","year":"2017","journal-title":"J Mol Biol"},{"key":"R43-4-20240828","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00239-004-0046-3","article-title":"Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements","volume":"60","author":"Mojica","year":"2005","journal-title":"J Mol Evol"},{"key":"R44-4-20240828","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1099\/mic.0.27437-0","article-title":"CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies","volume":"151","author":"Pourcel","year":"2005","journal-title":"Microbiology (Reading"},{"key":"R45-4-20240828","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/mt.2015.220","article-title":"In vivo CRISPR\/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa","volume":"24","author":"Bakondi","year":"2016","journal-title":"Mol Ther"},{"key":"R46-4-20240828","doi-asserted-by":"crossref","first-page":"14716","DOI":"10.1038\/ncomms14716","article-title":"Nrl knockdown by AAV-delivered CRISPR\/Cas9 prevents retinal degeneration in mice","volume":"8","author":"Yu","year":"2017","journal-title":"Nat Commun"},{"key":"R47-4-20240828","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41434-021-00258-6","article-title":"Restoration of RPGR expression in vivo using CRISPR\/Cas9 gene editing","volume":"29","author":"Gumerson","year":"2022","journal-title":"Gene Ther"},{"key":"R48-4-20240828","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.ymthe.2017.05.015","article-title":"Using CRISPR-Cas9 to generate gene-corrected autologous iPSCs for the treatment of inherited retinal degeneration","volume":"25","author":"Burnight","year":"2017","journal-title":"Mol Ther"},{"key":"R49-4-20240828","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: Challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials"},{"key":"R50-4-20240828","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nbt.3198","article-title":"Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells","volume":"33","author":"Chu","year":"2015","journal-title":"Nat Biotechnol"},{"key":"R51-4-20240828","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neuron.2011.06.004","article-title":"Optogenetics in neural systems","volume":"71","author":"Yizhar","year":"2011","journal-title":"Neuron"},{"key":"R52-4-20240828","doi-asserted-by":"crossref","first-page":"10380","DOI":"10.1523\/JNEUROSCI.3863-06.2006","article-title":"Next-generation optical technologies for illuminating genetically targeted brain circuits","volume":"26","author":"Deisseroth","year":"2006","journal-title":"J Neurosci"},{"key":"R53-4-20240828","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nmeth.f.324","article-title":"Optogenetics","volume":"8","author":"Deisseroth","year":"2011","journal-title":"Nat Methods"},{"key":"R54-4-20240828","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/newbio233149a0","article-title":"Rhodopsin-like protein from the purple membrane of Halobacterium halobium","volume":"233","author":"Oesterhelt","year":"1971","journal-title":"Nat New Biol"},{"key":"R55-4-20240828","doi-asserted-by":"crossref","first-page":"35033","DOI":"10.1074\/jbc.M806353200","article-title":"Monitoring light-induced structural changes of Channelrhodopsin-2 by UV-visible and Fourier transform infrared spectroscopy","volume":"283","author":"Ritter","year":"2008","journal-title":"J Biol Chem"},{"key":"R56-4-20240828","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nn.2120","article-title":"Red-shifted optogenetic excitation: A tool for fast neural control derived from Volvox carteri","volume":"11","author":"Zhang","year":"2008","journal-title":"Nat Neurosci"},{"key":"R57-4-20240828","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","article-title":"Partial recovery of visual function in a blind patient after optogenetic therapy","volume":"27","author":"Sahel","year":"2021","journal-title":"Nat Med"},{"key":"R58-4-20240828","first-page":"374","article-title":"Optogenetics for retinal disorders","volume":"9","author":"Henriksen","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"key":"R59-4-20240828","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuron.2006.02.026","article-title":"Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration","volume":"50","author":"Bi","year":"2006","journal-title":"Neuron"},{"key":"R60-4-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2021.11.009","article-title":"In vivo optogenetic stimulation of the primate retina activates the visual cortex after long-term transduction","volume":"24","author":"Chaffiol","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R61-4-20240828","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1167\/iovs.07-0032","article-title":"Neural reprogramming in retinal degeneration","volume":"48","author":"Marc","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R62-4-20240828","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1017\/S0952523814000212","article-title":"Optogenetic approaches to retinal prosthesis","volume":"31","author":"Barrett","year":"2014","journal-title":"Vis Neurosci"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_78_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:11:02Z","timestamp":1787757062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_78_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_78_22","relation":{},"ISSN":["1016-3190"],"issn-type":[{"value":"1016-3190","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}